羟乙基淀粉 vs 晶体液治疗脓毒血症和感染性休克患者德国 SepNet VISEP 试验结果(英文)课件.pptVIP

  • 7
  • 0
  • 约2.24千字
  • 约 51页
  • 2018-06-23 发布于贵州
  • 举报

羟乙基淀粉 vs 晶体液治疗脓毒血症和感染性休克患者德国 SepNet VISEP 试验结果(英文)课件.ppt

羟乙基淀粉 vs 晶体液治疗脓毒血症和感染性休克患者德国 SepNet VISEP 试验结果(英文)课件

3,170 ml HES;Hemodynamic effects;;;;;Effects on renal function;75.00;;;Mean SOFA Score;0.001;;;;VISEP Trial (HES vs. Ringers′ Lactate) - HES 22 ml/kg/BW -;;Progression of mortality from 28 days to 90 days;100;0.003;;0.615;;0.142;Volume resuscitation with HES 10% (200/0.5) results in faster hemodynamic stabilisation. Acute renal failure and need for renal replacement therapy occurred more often in the HES group 28-day mortality is not significantly different between study groups 90-day mortality tends to be higher (33.9% vs 41.0% (p=0.11) in the HES group ;Increasing cumulative dosages of H

您可能关注的文档

文档评论(0)

1亿VIP精品文档

相关文档